论文部分内容阅读
白三烯受体拮抗剂 (LTRAs)是近年来发展起来的一类新型非类固醇类平喘和抗炎药 ,国外已用来治疗哮喘并取得了较好疗效。它在炎症与免疫方面的作用也日益受到重视。LTRAs可以抑制气道炎症细胞的黏附、聚集和增殖 ;诱导细胞凋亡 ;影响细胞因子和炎症介质的释放 ;降低气道高反应性 ;减少气道黏液分泌 ;抑制气道重塑和抗肺纤维化 ;降低呼出气中的NO含量。另外 ,在其它组织中它也具有一定的抗炎作用。最近发现它在免疫系统的调节中可能也有较大的影响。LTRAs是一类具有多种作用、高效、低毒、安全性好的平喘抗炎药。具有广阔的应用前景。
Leukotriene receptor antagonists (LTRAs) are a new class of nonsteroidal antiasthmatic and anti-inflammatory drugs developed in recent years. They have been used to treat asthma in foreign countries and have achieved good results. Its role in inflammation and immunity is also increasingly valued. LTRAs can inhibit the adhesion, aggregation and proliferation of airway inflammatory cells; induce apoptosis; affect the release of cytokines and inflammatory mediators; reduce airway hyperresponsiveness; reduce airway mucus secretion; inhibit airway remodeling and anti-pulmonary fibrosis ; Reduce exhaled breath of NO content. In addition, it also has some anti-inflammatory effects in other tissues. It has recently been found that it may also have a greater impact on the regulation of the immune system. LTRAs are a class of antiasthmatic anti-inflammatory drugs with various functions, high efficiency, low toxicity and good safety. have a broad vision of application.